Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exemestane in Advanced and Recurrent Endometrial Carcinoma
NCT01965080Phase 2Completed
- Sponsor
- Nordic Society of Gynaecological Oncology Clinical Trial Unit
- Start
- Mar 2004
- Primary completion
- Feb 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of exemestane in endometrial cancer (EC), sponsored by Nordic Society of Gynaecological Oncology Clinical Trial Unit. Primary endpoint: Response rate at 6 months. Started Mar 2004; status: completed.
02
Drugs
exemestane
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT01965080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01965080.